BUY Alert News ! LOS ANGELES, Nov. 13, 2017 /PRNewswire/ -- CytRx today will continue to provide updates on the progress of both aldoxorubicin (by its licensee NantCell) and to meet with certain new prospective shareholders.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.